Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis

被引：0

作者：

Pons, Marion ^{[1
]}

Georgiadis, Stylianos ^{[1
]}

Ostergaard, Mikkel ^{[1
,4
]}

Ahmadzay, Zohra Faizy ^{[1
,4
]}

Glintborg, Bente ^{[1
,2
,3
,4
]}

Heberg, Jette ^{[1
]}

Christensen, Sara Nysom ^{[1
]}

Rasmussen, Simon ^{[1
]}

Loft, Anne Gitte ^{[5
,6
]}

Castrejon, Isabel ^{[7
,8
]}

Sanchez-Alonso, Fernando ^{[9
]}

Iannone, Florenzo ^{[10
]}

Nordstrom, Dan ^{[11
,12
]}

Hokkanen, Anna-Mari ^{[11
,12
]}

Ciurea, Adrian

Nissen, Michael J. ^{[13
]}

Zavada, Jakub ^{[14
,15
]}

Pavelka, Karel ^{[14
,15
]}

Rotar, Ziga ^{[16
,17
]}

Pirkmajer, Katja Perdan ^{[16
,17
]}

Michelsen, Brigitte ^{[1
,18
,19
]}

Mielnik, Pawel ^{[20
]}

Bernardes, Miguel ^{[21
]}

Khmelinskii, Nikita ^{[22
]}

Laas, Karin ^{[23
]}

Vorobjov, Sigrid ^{[24
]}

Codreanu, Catalin ^{[25
]}

Macfarlane, Gary J. ^{[26
]}

Jones, Gareth T. ^{[26
]}

Gudbjornsson, Bjorn ^{[27
,28
]}

Palsson, Olafur ^{[28
,29
]}

Wallman, Johan K. ^{[29
]}

van der Horst-bruinsma, Irene ^{[30
]}

Onen, Fatos ^{[31
]}

Hetland, Merete Lund ^{[1
,4
]}

Ornbjerg, Lykke Midtboll ^{[1
]}

机构：

[1] Rigshosp, Copenhagen Ctr Arthrit Res COPECARE, Ctr Rheumatol & Spine Dis, Ctr Head & Orthopaed, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark

[2] DANBIO, Glostrup, Denmark

[3] Copenhagen Ctr Arthrit Res COPECARE, Glostrup, Denmark

[4] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

[5] Aarhus Univ Hosp, Dept Rheumatol, Aarhus, Denmark

[6] Aarhus Univ, Dept Clin Med, Aarhus, Denmark

[7] Univ Gregorio Maranon, Hosp Gen, Dept Rheumatol, Madrid, Spain

[8] Univ Complutense Madrid, Fac Med, Madrid, Spain

[9] Spanish Soc Rheumatol, Res Unit, Madrid, Spain

[10] Univ Bari, Rheumatol Unit, DiMePReJ, Bari, Italy

[11] Helsinki Univ Hosp, Dept Med, Helsinki, Finland

[12] Helsinki Univ Hosp, Dept Rheumatol, Helsinki, Finland

[13] Geneva Univ Hosp, Dept Rheumatol, Geneva, Switzerland

[14] Inst Rheumatol, Prague, Czech Republic

[15] Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic

[16] Univ Med Ctr Ljubljana, Dept Rheumatol, Ljubljana, Slovenia

[17] Univ Ljubljana, Fac Med, Ljubljana, Slovenia

[18] Diakonhjemmet Hosp, Ctr Treatment Rheumat & Musculoskeletal Dis REMEDY, Oslo, Norway

[19] Sorlandet Hosp, Res Unit, Kristiansand, Norway

[20] Helse Forde, Sect Rheumatol, Dept Neurol Rheumatol & Phys Med, Forde, Norway

[21] Univ Porto, Fac Med, Dept Med, Rheumatol Dept,Ctr Hosp & Univ Sao Joao, Porto, Portugal

[22] Univ Lisbon, Fac Med, Lisbon Acad Med Ctr, Inst Med Mol,Rheumatol Res Unit, Lisbon, Portugal

[23] East Tallinn Cent Hosp, Dept Rheumatol, Tallinn, Estonia

[24] Natl Inst Hlth Dev, Tallinn, Estonia

[25] Univ Med & Pharm, Ctr Rheumat Dis, Bucharest 050472, Romania

[26] Univ Aberdeen, Aberdeen Ctr Arthrit & Musculoskeletal Hlth, Epidemiol Grp, Aberdeen, Scotland

[27] Landspitali Univ Hosp, Ctr Rheumatol Res, Reykjavik, Iceland

[28] Univ Iceland, Fac Med, Reykjavik, Iceland

[29] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Rheumatol, Lund, Sweden

[30] Radboud Univ Nijmegen, Med Ctr, Rheumatol, Nijmegen, Netherlands

[31] Dokuz Eylul Univ, Sch Med, Dept Internal Med, Div Rheumatol, Izmir, Turkiye

来源：

JOINT BONE SPINE | 2025年 / 92卷 / 03期

关键词：

Spondyloarthritis; Epidemiology; bDMARD; NECROSIS-FACTOR INHIBITORS; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; ANKYLOSING-SPONDYLITIS; EULAR RECOMMENDATIONS; RHEUMATOID-ARTHRITIS; DISEASE-ACTIVITY; DOUBLE-BLIND; REMISSION; DRUG; COMEDICATION;

D O I：

10.1016/j.jbspin.2024.105824

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months. Patients and methods: Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/>= 2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses. Results: The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD na & iuml;ve patients, a higher risk of withdrawal from secukinumab was found for those with >= 2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD na & iuml;ve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD na & iuml;ve patients compared to patients with >= 2 prior b/tsDMARDs at 24 months in axSpA and PsA. Conclusion: This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD na & iuml;ve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure. (c) 2024 Les Auteurs. Publie par Elsevier Masson SAS au nom de Socioto Franoaise de Rhumatologie. Cet article est publie en Open Access sous licence CC BY (http://creativecommons.org/licenses/by/4.0/).

引用

页数：13

共 50 条

[1] Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO
[2] 2-F
[3] [Anonymous], About Us
[4] Arida Aikaterini, 2015, J Rheumatol, V42, P2098, DOI 10.3899/jrheum.150316
[5] Multiple imputation by chained equations: what is it and how does it work?
Azur, Melissa J.
Stuart, Elizabeth A.
Frangakis, Constantine
Leaf, Philip J.
[J]. INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH, 2011, 20 (01) : 40 - 49
[6] Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Baeten, Dominique
Baraliakos, Xenofon
Braun, Juergen
Sieper, Joachim
Emery, Paul
van der Heijde, Desiree
McInnes, Iain
van Laar, Jacob M.
Landewe, Robert
Wordsworth, Paul
Wollenhaupt, Juergen
Kellner, Herbert
Paramarta, Jacqueline
Wei, Jiawei
Brachat, Arndt
Bek, Stephan
Laurent, Didier
Li, Yali
Wang, Ying A.
Bertolino, Arthur P.
Gsteiger, Sandro
Wright, Andrew M.
Hueber, Wolfgang
[J]. LANCET, 2013, 382 (9906) : 1705 - 1713
[7] Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Braun, Juergen
Baraliakos, Xenofon
Deodhar, Atul
Baeten, Dominique
Sieper, Joachim
Emery, Paul
Readie, Aimee
Martin, Ruvie
Mpofu, Shephard
Richards, Hanno B.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 1070 - 1077
[8] Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis
Braun, Juergen
Baraliakos, Xenofon
Heldmann, Frank
Kiltz, Uta
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (05) : 647 - 659
[9] CALIN A, 1994, J RHEUMATOL, V21, P2281
[10] One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study
Chimenti, Maria Sole
Fonti, Giulia Lavinia
Conigliaro, Paola
Sunzini, Flavia
Scrivo, Rossana
Navarini, Luca
Triggianese, Paola
Peluso, Giusy
Scolieri, Palma
Caccavale, Rosalba
Diamanti, Andrea Picchianti
De Martino, Erica
Salemi, Simonetta
Birra, Domenico
Altobelli, Alessio
Paroli, Marino
Bruzzese, Vincenzo
Lagana, Bruno
Gremese, Elisa
Conti, Fabrizio
Afeltra, Antonella
Perricone, Roberto
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (07) : 813 - 821

← 1 2 3 4 5 →